Uni Eropa - Portugis - EMA (European Medicines Agency)

merck sharp & dohme b.v. - raltegravir - infecções por hiv - antivirais para uso sistêmico - isentress é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento do vírus da imunodeficiência humana (hiv 1) infecção.

Uni Eropa - Portugis - EMA (European Medicines Agency)

sanquin plasma products b.v. - fator ix de coagulação humana - hemofilia b - anti-hemorrágicos - tratamento e profilaxia do sangramento em pacientes com hemofilia b (deficiência congênita de factor ix).

Uni Eropa - Portugis - EMA (European Medicines Agency)

theramex ireland limited - acetato de nomegestrol, estradiol - contracepção - hormônios sexuais e moduladores do sistema genital, - oral contraception,.

Uni Eropa - Portugis - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - fibrinogénio humano, trombina humana - hemostasia, cirúrgica - anti-hemorrágicos - tratamento de suporte onde as técnicas cirúrgicas padrão são insuficientes para melhorar a hemostasia. raplixa deve ser usado em combinação com um aprovados esponja de gelatina. raplixa é indicado em adultos com mais de 18 anos de idade.

Uni Eropa - Portugis - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasias colorretais - antineoplastic agents, protein kinase inhibitors - stivarga é indicado como monoterapia para o tratamento de pacientes adultos com:câncer colorretal metastático (crc), que foram previamente tratados com, ou que não são considerados candidatos para, terapias disponíveis - estes incluem fluoropyrimidine base de quimioterapia, um anti-vegf terapia e um anti-egfr terapia;ou metastático, irressecável tumores estromais gastrointestinais (gist), que progrediu ou são intolerantes antes do tratamento com imatinib e sutent;carcinoma hepatocelular (chc), que foram previamente tratados com sorafenib.

Uni Eropa - Portugis - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia é indicado para o tratamento de pacientes adultos com localmente avançado ou metastático, nsclc após quimioterapia prévia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia é indicado para o tratamento de pacientes adultos com localmente avançado ou metastático, nsclc após quimioterapia prévia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Uni Eropa - Portugis - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - outros agentes antineoplásicos - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Brasil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

glaxosmithkline brasil ltda - cloridrato de tansulosina, dutasterida - outros produtos com acao no trato urinario

Brasil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

fresenius medical care ltda - cloreto de sÓdio, cloreto de potÁssio, cloreto de cÁlcio, cloreto de magnÉsio hexaidratado - produtos para hemodialise

Brasil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - cloridrato de midazolam, maleato de midazolam - ansioliticos simples